GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Parnell Pharmaceuticals Holdings Ltd (OTCPK:PARNF) » Definitions » Gross-Profit-to-Asset %

PARNF (Parnell Pharmaceuticals Holdings) Gross-Profit-to-Asset % : 47.26% (As of Dec. 2018)


View and export this data going back to 2014. Start your Free Trial

What is Parnell Pharmaceuticals Holdings Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Parnell Pharmaceuticals Holdings's annualized Gross Profit for the quarter that ended in Dec. 2018 was $11.13 Mil. Parnell Pharmaceuticals Holdings's average Total Assets over the quarter that ended in Dec. 2018 was $23.55 Mil. Therefore, Parnell Pharmaceuticals Holdings's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2018 was 47.26%.


Parnell Pharmaceuticals Holdings Gross-Profit-to-Asset % Historical Data

The historical data trend for Parnell Pharmaceuticals Holdings's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Parnell Pharmaceuticals Holdings Gross-Profit-to-Asset % Chart

Parnell Pharmaceuticals Holdings Annual Data
Trend Jun12 Jun13 Jun14 Dec15 Dec16 Dec17 Dec18
Gross-Profit-to-Asset %
Get a 7-Day Free Trial 8.48 22.52 21.62 24.71 47.26

Parnell Pharmaceuticals Holdings Semi-Annual Data
Jun12 Jun13 Jun14 Dec15 Dec16 Dec17 Dec18
Gross-Profit-to-Asset % Get a 7-Day Free Trial 7.06 22.52 21.62 24.71 47.26

Competitive Comparison of Parnell Pharmaceuticals Holdings's Gross-Profit-to-Asset %

For the Drug Manufacturers - Specialty & Generic subindustry, Parnell Pharmaceuticals Holdings's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Parnell Pharmaceuticals Holdings's Gross-Profit-to-Asset % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Parnell Pharmaceuticals Holdings's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Parnell Pharmaceuticals Holdings's Gross-Profit-to-Asset % falls into.



Parnell Pharmaceuticals Holdings Gross-Profit-to-Asset % Calculation

Parnell Pharmaceuticals Holdings's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2018 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2018 )/( (Total Assets (A: Dec. 2017 )+Total Assets (A: Dec. 2018 ))/ count )
=11.128/( (23.092+24.003)/ 2 )
=11.128/23.5475
=47.26 %

Parnell Pharmaceuticals Holdings's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2018 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Dec. 2018 )/( (Total Assets (Q: Dec. 2017 )+Total Assets (Q: Dec. 2018 ))/ count )
=11.128/( (23.092+24.003)/ 2 )
=11.128/23.5475
=47.26 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is one times the annual (Dec. 2018) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Parnell Pharmaceuticals Holdings Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Parnell Pharmaceuticals Holdings's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Parnell Pharmaceuticals Holdings Business Description

Traded in Other Exchanges
N/A
Address
476 Gardeners Road, Unit 4, Century Estate, Alexandria, Sydney, NSW, AUS, 2015
Parnell Pharmaceuticals Holdings Ltd is an Australia based veterinary pharmaceutical company. It is focused on developing, manufacturing and commercializing animal health solutions. The group manufactures and market products for companion animals and production animals. The firm also has a pipeline of drug products like Zydax, PAR121 and PAR122 and Luminous which covers therapeutic areas in orthopedics, dermatology, and nutraceuticals. The operating segments of the company are Companion animal, Production animal - U.S., Production animal - rest of world and Contract Manufacturing. It operates internationally and generates the majority of the revenue from the Production animal - U.S. segment which covers the group's reproductive hormone portfolio across production animal in the USA.